Karine Briot

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

Karl Insogna, Karine Briot, Erik A. Imel et al. · Journal of Bone and Mineral Research · 2018 · 329 citations · Full text

Sclerostin, Human Growth, Immunology +21

Therapeutic management of hypophosphatemic rickets from infancy to adulthood

Agnès Linglart, Martin Biosse Duplan, Karine Briot et al. · Endocrine Connections · 2014 · 322 citations · Full text

Electrolyte Disorder, Pharmacotherapy, Osteoporosis +16

Mild prevalent and incident vertebral fractures are risk factors for new fractures

Christian Roux, J. Fechtenbaum, S. Kolta et al. · Osteoporosis International · 2007 · 160 citations

Skeletal Trauma, Bone Disease, New Fractures +8

Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms

Hélène Che, Christian Roux, Adrien Etcheto et al. · European Journal of Endocrinology · 2016 · 159 citations · Full text

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Anthony A. Portale, Thomas O. Carpenter, Maria Luisa Brandi et al. · Calcified Tissue International · 2019 · 153 citations · Full text